User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin.

Primary tabs

Vander Borght, Sara Komuta, Mina Libbrecht, Louis [UCL] Katoonizadeh, Aezam Aerts, Raymond Roskams, Tania

BACKGROUND: Hepatocellular carcinoma (HCC) responds poorly to chemotherapy owing to multidrug resistance (MDR). Recent studies showed that part of HCC could be of progenitor cell origin. Because some MDR-conferring transporters [multidrug resistance-associated protein 1 (MRP1), MDR1, MRP3 and breast cancer resistance protein (BCRP)] are expressed in hepatic progenitor cells (HPCs), expression in HCC might reflect a progenitor cell origin and provide the tumour cells with a MDR phenotype. METHODS: The transcriptional profile of transporter genes was assessed in 139 HCCs earlier subjected to global gene expression analysis. In addition, we performed real-time reverse transcriptase-polymerase chain reaction and immunohistochemistry for MRP1, MRP3, MDR1, BCRP and biliary/HPC markers keratin 7 and/or keratin 19 (K7/K19) on an independent set of 23 HCCs and surrounding liver. RESULTS: Micro-array analysis showed that MRP1 was the only transporter with increased mRNA levels in HCC compared with the surrounding tissue. MRP1 mRNA levels were significantly higher in HCCs with poor survival and the 'hepatoblast subtype' of HCC, thought to be derived from HPCs. In 11 of 23 HCCs of the independent set, we found a diffuse protein expression of MRP1 compared with negative hepatocytic expression observed in normal (surrounding) hepatocytes. MRP1 was expressed in K19(+) non-neoplastic HPCs and K19(+) tumour cells. In addition, MRP3 and BCRP were expressed in K7/K19(+) tumour cells. MRP1 expression was high in poorly differentiated HCCs, large tumours (>7 cm) and microvascular invasive tumours. CONCLUSIONS: MRP1 correlated with K19 mRNA and protein expression in two independent series of HCC. In addition, MRP1 was, together with MRP3 and BCRP, colocalized with K7/K19 in the tumour. Therefore, MRP1 expression could be a reflection of the HPC origin of this subgroup of HCCs and may result in an aggressive tumour phenotype.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2008
Language Anglais
Journal information "Liver International" - Vol. 28, no.10, p. 1370-1380 (2008)
Peer reviewed yes
Publisher Wiley-Blackwell Publishing, Inc. ((United States) Malden, MA)
issn 1478-3223
e-issn 1478-3231
Publication status Publié
Affiliation [KUL]
MESH Subject Carcinoma, Hepatocellular ; Stem Cells ; Cell Line, Tumor ; Gene Expression Profiling ; Humans ; Immunohistochemistry ; Microarray Analysis ; Multidrug Resistance-Associated Proteins ; Reverse Transcriptase Polymerase Chain Reaction ; Statistics, Nonparametric
Keywords ATP-binding cassette transporters ; Hepatic progenitor cell ; Hepatocellular carcinoma ; Keratin 19 ; Multidrug resistance ; Multidrug resistance-associated protein 1
Links
  1. Parkin, GLOBOCAN 2000, 94, 153 (2001)
  2. Adler, Liver Transpl, 14, 526 (2008)
  3. Befeler, diagnosis and treatment, 122, 1609 (2002)
  4. Llovet, resection versus transplantation, 30, 1434 (1999)
  5. Schwartz, review of the randomised clinical trials, 3, 593 (2002)
  6. Han, Curr Med Chem Anticancer Agents, 4, 31 (2004)
  7. Lage, implications on drug resistance from microorganisms to human cancers, 22, 188 (2003)
  8. Bradley, Cancer Res, 52, 5154 (1992)
  9. Kato, J Surg Oncol, 78, 110 (2001)
  10. Liu, FRCS(Edin) Chi L., Fan, MD Sheung T., Ng, FRCP(UK) Matthew, Ng, MD Irene O.L., Expression of P-Glycoprotein in Hepatocellular Carcinoma, 10.1309/ac1m-4ty4-u0tn-en7t
  11. Lai, Cancer, 66, 1685 (1990)
  12. Richart, Dig Dis Sci, 47, 2454 (2002)
  13. Takanishi, Oncology, 54, 231 (1997)
  14. Vander Borght, J Pathol, 207, 471 (2005)
  15. Zollner, Liver Int, 25, 367 (2005)
  16. Ros, J Pathol, 200, 553 (2003)
  17. Ros, Gut, 52, 1060 (2003)
  18. Vander Borght, possible functional consequences, 54, 1051 (2006)
  19. Lee, Nat Med, 12, 410 (2006)
  20. Robrechts, a progenitor cell tumour?, 18, 288 (1998)
  21. Roskams, Oncogene, 25, 3818 (2006)
  22. Lee, Hepatology, 40, 667 (2004)
  23. Durnez, Histopathology, 49, 138 (2006)
  24. Uenishi, Cancer Sci, 94, 851 (2003)
  25. Vaneyken, Human Pathol, 19, 562 (1988)
  26. Wu, Am J Pathol, 149, 1167 (1996)
  27. Aishima, Am J Surg Pathol, 31, 783 (2007)
  28. Roelofsen, Gastroenterology, 112, 511 (1997)
  29. Edmondson, a study of 100 cases among 48,900 necropsies, 7, 462 (1954)
  30. Hsia, Hepatology, 16, 1327 (1992)
  31. Kim, J Hepatol, 40, 298 (2004)
  32. Nies, Int J Cancer, 94, 492 (2001)
  33. Leslie, Toxicology, 167, 3 (2001)
  34. Laupeze, Life Sci, 68, 1323 (2001)
  35. Oselin, Eur J Haematol, 71, 119 (2003)
  36. Franco, J Biol Chem, 282, 30452 (2007)
  37. Hammond, J Biol Chem, 282, 14337 (2007)
  38. Berger, prognostic implications, 131, 355 (2005)
  39. Filipits, the Austrian breast and colorectal cancer study group, 23, 1161 (2005)
Bibliographic reference Vander Borght, Sara ; Komuta, Mina ; Libbrecht, Louis ; Katoonizadeh, Aezam ; Aerts, Raymond ; et. al. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin.. In: Liver International, Vol. 28, no.10, p. 1370-1380 (2008)
Permanent URL http://hdl.handle.net/2078/187387